CD274 and neoplasm: Despite investigations into several biomarkers expressed by tumor cells and their microenvironment, the immunohistochemical (IHC) evaluation of PD‐L1 still remains one of the most important predictive biomarkers for PD1/PD‐L1 immunotherapy.1, 4